for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shandong Buchang Pharmaceuticals Co Ltd

603858.SS

Latest Trade

19.78CNY

Change

-0.14(-0.70%)

Volume

6,562,351

Today's Range

19.69

 - 

19.92

52 Week Range

17.93

 - 

25.85

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
19.92
Open
19.88
Volume
6,562,351
3M AVG Volume
157.47
Today's High
19.92
Today's Low
19.69
52 Week High
25.85
52 Week Low
17.93
Shares Out (MIL)
1,141.58
Market Cap (MIL)
22,580.46
Forward P/E
--
Dividend (Yield %)
6.28

Latest Developments

More

Shandong Buchang Pharma Plans Funding Via Bonds, Medium-term Notes Issue

Lock-Up Period For Shandong Buchang Pharmaceuticals' 598.2 Mln Shares To End

Shandong Buchang Pharmaceuticals' 9-Mth Net Profit Up 11.0% Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shandong Buchang Pharmaceuticals Co Ltd

SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Company’s main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.

Industry

Major Drugs

Contact Info

No. 369, Zhonghua West Road

+86.530.5299167

http://www.buchang.com/

Executive Leadership

Tao Zhao

Chairman of the Board

Chao Zhao

President, Director

Yimin Wang

Vice Chairman of the Board, Vice President

Jing Zhao

Vice Chairman of the Board

Baocai Wang

Chief Financial Officer

Key Stats

Price To Earnings (TTM)
12.20
Price To Sales (TTM)
1.54
Price To Book (MRQ)
1.73
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
19.72
LT Debt To Equity (MRQ)
6.46
Return on Investment (TTM)
14.27
Return on Equity (TTM)
10.36

Latest News

Latest News

BRIEF-Shandong Buchang Pharmaceuticals announces 2017 dividend payment plan

* Says it plans to pay a cash dividend of 16.14 yuan (pre-tax) for every 10 shares and use additional paid-in capital to distribute 3 new shares for every 10 shares, as the dividend payment plan for 2017

BRIEF-Shandong Buchang Pharmaceuticals unit obtains high-tech enterprise recognition

* Says its unit will enjoy tax preference of 15 percent for three years from Dec. 28, 2017

BRIEF-Shandong Buchang Pharmaceuticals unit signs pharmaceutical technology development contract worth 3.5 mln yuan

* Says its unit signs pharmaceutical technology development contract worth 3.5 million yuan

BRIEF-Shandong Buchang Pharmaceuticals to sell 7.3 pct stake in pharmacy firm worth 15 mln yuan

* Says it plans to sell 7.3 percent stake in a pharmacy firm worth 15 million yuan

BRIEF-Shandong Buchang Pharmaceuticals gets FDA new drug approval for Metoprolol Succinate Extended-Release Tablets

* Says its new drug Metoprolol Succinate Extended-Release Tablets gets new drug approval(ANDA) from FDA

BRIEF-Shandong Buchang Pharmaceuticals proposes FY 2017 cash dividend payment plan

* Controlling shareholder proposed to pay a cash dividend of 16.14 yuan(pre-tax) for every 10 shares and use additional paid-in capital to distribute 3 new shares for every 10 shares, as FY 2017 dividend payment plan

BRIEF-Shandong Buchang Pharmaceuticals, Units Received Subsidies Totalling 277.9 Mln Yuan

* SAYS IT AND UNITS RECEIVED GOVERNMENT SUBSIDIES TOTALLING 277.9 MILLION YUAN ($42.77 million) FROM JAN 3, 2017 TO JAN 3, 2018 Source text in Chinese: http://bit.ly/2lM2hR4 Further company coverage: ($1 = 6.4980 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Shandong Buchang Pharmaceuticals To Apply For 1 Bln Yuan Financing From China Minsheng Banking

* SAYS IT PLANS TO APPLY FOR FINANCING OF 1.0 BILLION YUAN ($152.53 million) FROM CHINA MINSHENG BANKING CORP Source text in Chinese: http://bit.ly/2DjdaAa Further company coverage: ($1 = 6.5561 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Shandong Buchang Pharmaceuticals unit obtains high-tech enterprise recognition and to enjoy tax preference

* Says its unit was recognized as high-tech enterprise, and to enjoy a tax preference of 15 percent for three years from 2017 to 2019

BRIEF-Jointown Pharmaceutical Group plans medical JV with partner

* Says it enters into strategic cooperation agreement with Shandong Buchang Pharmaceuticals Co Ltd

BRIEF-Lock-up period for Shandong Buchang Pharmaceuticals' 258 mln shares to end

* Says lock-up period for 258.0 million shares to end, shares to start trading on Nov 20

BRIEF-Shandong Buchang Pharmaceuticals unit receives GMP certificate

* Says its wholly owned unit received goods manufacture practice (GMP) certificate from Hebei Food and Drug Administration

BRIEF-Shandong Buchang Pharmaceuticals plans cooperation with Nantong pharma

* Says co is in deal with a Nantong-based pharma firm, regarding cooperation on development, supplement and sale of five drug products

BRIEF-Shandong Buchang Pharmaceuticals adopts new accounting policy regarding subsidy

* Says it adopted new accounting policy regarding subsidy, effective since June 12

BRIEF-Shandong Buchang Pharmaceuticals' H1 net profit up 12.0 pct y/y

* Says H1 net profit up 12.0 percent y/y at 678.1 million yuan ($101.64 million)

BRIEF-Shandong Buchang Pharmaceuticals wins 20 pct stake in pharmaceuticals firm for 40.4 mln yuan

* Says it won 20 percent stake in a 80 percent owned pharmaceuticals firm for 40.4 million yuan

BRIEF-Shandong Buchang Pharmaceuticals completes establishment of tech firm in Beijing

* Says it completes establishment of tech firm in Beijing city, on May 14

BRIEF-Shandong Buchang Pharmaceuticals to buy real estate property worth 175.3 mln yuan

* Says it plans to buy real estate property located in Shandong Heze city at 175.3 million yuan

BRIEF-Shandong Buchang Pharmaceuticals unit receives approval for drug clinical trials

* Says its unit has been granted approval for drug clinical trials for BC0335 APIs and BC0335 granules issued by china food and drug administration

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up